Feline Infectious Peritonitis FIP Treatment GS-441524

Colleague,

My infectious disease specialist is unavailable at the moment, but this is a topic I manage frequently. Based on the data you've provided—a young cat with a high-protein, Rivalta-positive effusion, hyperglobulinemia, and a low A:G ratio—your presumptive diagnosis of effusive FIP is sound. The positive coronavirus titer supports this but is not diagnostic on its own; the combination of findings, however, gives this a very high index of suspicion.

Here's my approach to the current treatment landscape:

Primary Therapy: GS-441524
This is the standard of care. The transformation in prognosis has been one of the most remarkable developments in my career.
* Dosing: For the effusive ("wet") form without ocular or neurologic signs, the starting dose is 6 mg/kg SQ daily. The course is a minimum of 84 days. It's critical to dose-escalate immediately to 8-10 mg/kg if neuro/ocular signs develop. I recommend re-weighing the cat weekly and adjusting the dose accordingly, as they should be gaining weight.
* Acquisition: This remains the primary challenge. The FDA recently approved a related compound, remdesivir for injection (Veklury), for treating FIP, which is a major step forward. However, access and cost can still be prohibitive. Compounding pharmacies are another avenue for obtaining GS-441524, though quality control varies. Owner support groups online are often the most practical resource for sourcing, but this requires a frank conversation with the client about using unregulated products.

Oral Alternatives: Molnupiravir
Molnupiravir is an emerging oral option. It's appealing due to ease of administration, especially for fractious cats or owners who cannot give injections. The data is less robust than for GS-441524, and dosing protocols are still being refined. It's a reasonable consideration, particularly if injections are not feasible, but GS remains my first choice.

Monitoring for Remission
Success is defined by both clinical and laboratory resolution.
* Clinical: Expect rapid improvement. Fever should resolve in 12-36 hours, appetite and activity should return within days, and the effusion should begin to resolve within 1-2 weeks.
* Laboratory: Monitor weight gain weekly. Recheck a CBC and chemistry panel with globulins at weeks 4, 8, and 12 (end of treatment). The goal is normalization of total protein and globulins, and an A:G ratio >0.6. Treatment should not be stopped until these parameters are normal.

Prognosis and Relapse
The contrast is stark. Without treatment, FIP is uniformly fatal. With an appropriate course of GS-441524, the reported cure rate is over 85%. Relapses occur in 10-15% of cases, often due to an insufficient dose (especially with missed neuro involvement), too short a duration, or development of drug resistance. Relapses are typically retreated with a higher dose of GS or a different antiviral.

This is a manageable disease now, which was unthinkable a decade ago. The key is aggressive, consistent treatment and careful monitoring.

Confidence Level: High. The evidence for these antiviral agents is strong.

Colleague, this is one of the most significant therapeutic revolutions we've seen, moving FIP from a fatal diagnosis to a treatable disease. However, the pharmacology and regulatory landscape are complex. Let's break down the key considerations from a clinical pharmacology perspective.

GS-441524 (The Primary Metabolite)

GS-441524 is the active nucleoside analog that inhibits the viral RNA-dependent RNA polymerase. It is the primary metabolite of the human-approved prodrug, remdesivir.

* Sourcing & Legality: This is the main challenge. GS-441524 is not an FDA-approved drug for any species. The products available to veterinarians are sourced through unregulated channels, often via online owner communities. This means there are no guarantees of sterility, concentration, purity, or stability. While some compounding pharmacies may be willing to formulate it from bulk powder, the source and quality of that active pharmaceutical ingredient (API) are often unverifiable. This is a significant liability and quality control issue. The legally preferable, albeit often impractical, option under AMDUCA would be extra-label use of FDA-approved remdesivir (Veklury™).

* Dosing & Pharmacokinetics: The dose of 6 mg/kg SQ q24h you mentioned is appropriate for the uncomplicated effusive ("wet") form. Ocular or neurologic FIP requires higher doses (10-15 mg/kg) to achieve adequate concentrations across the blood-brain and blood-ocular barriers. The 84-day course is based on studies showing this duration is necessary to fully clear the virus and prevent relapse. Subcutaneous injections are often painful due to the acidic pH of the vehicle (cyclodextrin); oral tablet formulations are now available from the same unregulated sources and are often used after an initial injectable course, though bioavailability data is scarce.

Molnupiravir

This is another oral nucleoside analog that works by inducing "error catastrophe" during viral replication.

* Use & Dosing: It has shown efficacy in some studies, often dosed around 10-15 mg/kg PO BID. Its primary advantage is oral administration from the start.
* Safety Concerns: The mechanism carries a theoretical risk of host cell mutagenicity. While studies in cats have not demonstrated significant short-term adverse effects, it remains a long-term concern and a key pharmacological difference from GS-441524. It is generally considered a second-line option if GS-441524 is not tolerated or available.

Monitoring & Prognosis

Without therapeutic drug monitoring available, we rely on pharmacodynamic markers. You are correct to focus on globulin normalization, A:G ratio improvement (>0.6 is a good target), weight gain, and resolution of effusion. Failure of globulins to normalize by the end of the 84-day course is a strong predictor of relapse.

With treatment, the prognosis is excellent, with remission rates exceeding 85% in many studies. Without treatment, as you know, it remains nearly 100% fatal. The key to success is an accurate diagnosis, aggressive and uninterrupted treatment for the full duration, and dose escalation for neurologic or ocular disease. The primary hurdles remain the cost and the unregulated nature of the most effective drug.